The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy

Autor:	S, Lichtiger, D G, Binion, D C, Wolf, D H, Present, A G, Bensimon, E, Wu, A P, Yu, A T, Cardoso, J, Chao, P M, Mulani, K G, Lomax, J D, Kent
Rok vydání:	2010
Předmět:	Adult Male Work Wound Healing Fistula Adalimumab Anti-Inflammatory Agents Antibodies Monoclonal Efficiency Antibodies Monoclonal Humanized Abscess Infliximab Treatment Outcome Crohn Disease Quality of Life Humans Female
Zdroj:	Alimentary pharmacologytherapeutics. 32(10)
ISSN:	1365-2036
Popis:	Adalimumab induces and maintains remission in adults with Crohn's disease.To evaluate safety, fistula healing, quality of life and work productivity in adalimumab-treated patients who failed infliximab, including primary nonresponders.After a ≥8-week infliximab washout, patients with moderate-to-severe Crohn's disease received open-label adalimumab as induction (160/80 mg at weeks 0/2) and maintenance (40 mg every other week) therapies. At/after 8 weeks, patients with flare/nonresponse could receive weekly therapy. Minimum study duration was 8 weeks, continuing until the commercial availability of adalimumab for Crohn's disease.Of 673 patients enrolled, 17% were infliximab primary nonresponders and 83% were initial responders. Three percent of patients had serious infections (mainly abscesses). Complete fistula healing was achieved by 34/88 (39%) patients with baseline fistulas. Improvements in quality of life and work productivity were sustained from week 4 to week 24 for all patients, as well as the subgroup of primary nonresponders.Blinded clinical trials have shown adalimumab to be both an effective first-line therapy for anti-TNF-naïve patients and an important treatment option for infliximab-refractory or -intolerant patients. This trial presents open-label experience to support further the safety and effectiveness of adalimumab in patients who failed infliximab therapy, including primary nonresponders (NCT00338650).
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::7db4605410b27fc7511624a9562fddcd https://pubmed.ncbi.nlm.nih.gov/20955442 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.